Cargando…

Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A serological test is used to assess the efficacy of vaccination. It has been reported that anti-SARS-CoV-2 spike (S) and neutralizing antibody (Ab) levels are lower following vaccination i...

Descripción completa

Detalles Bibliográficos
Autores principales: Furukawa, Hiroshi, Oka, Shomi, Higuchi, Takashi, Nakama, Moriyuki, Nagai, Nobuhiro, Tohma, Shigeto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414304/
https://www.ncbi.nlm.nih.gov/pubmed/36016252
http://dx.doi.org/10.3390/vaccines10081365
_version_ 1784775955909181440
author Furukawa, Hiroshi
Oka, Shomi
Higuchi, Takashi
Nakama, Moriyuki
Nagai, Nobuhiro
Tohma, Shigeto
author_facet Furukawa, Hiroshi
Oka, Shomi
Higuchi, Takashi
Nakama, Moriyuki
Nagai, Nobuhiro
Tohma, Shigeto
author_sort Furukawa, Hiroshi
collection PubMed
description Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A serological test is used to assess the efficacy of vaccination. It has been reported that anti-SARS-CoV-2 spike (S) and neutralizing antibody (Ab) levels are lower following vaccination in patients with rheumatic disease. Here, we investigated anti-SARS-CoV-2 S and neutralizing Abs in vaccinated rheumatoid arthritis (RA) patients in Japan. Anti-SARS-CoV-2 S and neutralizing Abs were quantified in 101 RA patients and 117 controls. Anti-SARS-CoV-2 S Ab levels were lower in RA patients than both earlier after vaccination in controls (mean RA 324.1 ± 591.8 SDM vs. control 1216.6 ± 854.4 [U/mL], p < 0.0001) and later after vaccination (324.1 ± 591.8 vs. 582.0 ± 415.6 [U/mL], p = 0.0002). The interval between vaccination of the RA patients and serum collection was longer than for controls early after vaccination (142.1 ± 31.6 vs. 98.3 ± 11.2 [days], p < 0.0001), but shorter than the later sample from the controls (142.1 ± 31.6 vs. 257.3 ± 11.2 [days], p < 0.0001). Importantly, anti-SARS-CoV-2 neutralizing Ab titers in RA patients were higher than in either early or later control samples (10.7 ± 4.9 vs. 8.6 ± 6.6 [%], p = 0.0072, and 10.7 ± 4.9 vs. 3.1 ± 3.7 [%], p < 0.0001, respectively). Anti-SARS-CoV-2 S Ab titers in vaccinated RA patients were lower than in controls, but they were influenced by other clinical manifestations. Anti-SARS-CoV-2 neutralizing Ab levels were independently increased in RA.
format Online
Article
Text
id pubmed-9414304
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94143042022-08-27 Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients Furukawa, Hiroshi Oka, Shomi Higuchi, Takashi Nakama, Moriyuki Nagai, Nobuhiro Tohma, Shigeto Vaccines (Basel) Article Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A serological test is used to assess the efficacy of vaccination. It has been reported that anti-SARS-CoV-2 spike (S) and neutralizing antibody (Ab) levels are lower following vaccination in patients with rheumatic disease. Here, we investigated anti-SARS-CoV-2 S and neutralizing Abs in vaccinated rheumatoid arthritis (RA) patients in Japan. Anti-SARS-CoV-2 S and neutralizing Abs were quantified in 101 RA patients and 117 controls. Anti-SARS-CoV-2 S Ab levels were lower in RA patients than both earlier after vaccination in controls (mean RA 324.1 ± 591.8 SDM vs. control 1216.6 ± 854.4 [U/mL], p < 0.0001) and later after vaccination (324.1 ± 591.8 vs. 582.0 ± 415.6 [U/mL], p = 0.0002). The interval between vaccination of the RA patients and serum collection was longer than for controls early after vaccination (142.1 ± 31.6 vs. 98.3 ± 11.2 [days], p < 0.0001), but shorter than the later sample from the controls (142.1 ± 31.6 vs. 257.3 ± 11.2 [days], p < 0.0001). Importantly, anti-SARS-CoV-2 neutralizing Ab titers in RA patients were higher than in either early or later control samples (10.7 ± 4.9 vs. 8.6 ± 6.6 [%], p = 0.0072, and 10.7 ± 4.9 vs. 3.1 ± 3.7 [%], p < 0.0001, respectively). Anti-SARS-CoV-2 S Ab titers in vaccinated RA patients were lower than in controls, but they were influenced by other clinical manifestations. Anti-SARS-CoV-2 neutralizing Ab levels were independently increased in RA. MDPI 2022-08-21 /pmc/articles/PMC9414304/ /pubmed/36016252 http://dx.doi.org/10.3390/vaccines10081365 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Furukawa, Hiroshi
Oka, Shomi
Higuchi, Takashi
Nakama, Moriyuki
Nagai, Nobuhiro
Tohma, Shigeto
Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients
title Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients
title_full Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients
title_fullStr Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients
title_full_unstemmed Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients
title_short Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients
title_sort anti-sars-cov-2 spike antibody titers and neutralizing antibodies in vaccinated rheumatoid arthritis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414304/
https://www.ncbi.nlm.nih.gov/pubmed/36016252
http://dx.doi.org/10.3390/vaccines10081365
work_keys_str_mv AT furukawahiroshi antisarscov2spikeantibodytitersandneutralizingantibodiesinvaccinatedrheumatoidarthritispatients
AT okashomi antisarscov2spikeantibodytitersandneutralizingantibodiesinvaccinatedrheumatoidarthritispatients
AT higuchitakashi antisarscov2spikeantibodytitersandneutralizingantibodiesinvaccinatedrheumatoidarthritispatients
AT nakamamoriyuki antisarscov2spikeantibodytitersandneutralizingantibodiesinvaccinatedrheumatoidarthritispatients
AT nagainobuhiro antisarscov2spikeantibodytitersandneutralizingantibodiesinvaccinatedrheumatoidarthritispatients
AT tohmashigeto antisarscov2spikeantibodytitersandneutralizingantibodiesinvaccinatedrheumatoidarthritispatients